|
|
Post by akemp3000 on Nov 6, 2023 11:09:44 GMT -5
The unusual stock price drop before the quarterly call is based on lower than average daily volumes which is also unusual. This begs the question, who are these buyers and sellers establishing the low price and do they really know something behind the scenes that isn't obvious to others that track this company on a daily basis? If bad or disappointing news is truly anticipated by the street, it would seem the daily volume should be significantly higher. Just thinking out loud and wondering if the current price is truly indicative of what's coming in the call. Guess we'll find out shortly.
|
|
|
|
Post by cretin11 on Nov 6, 2023 11:22:16 GMT -5
My guess is there’s no bad or disappointing news coming in this call. On the other hand, there’s no surprisingly excellent news either. Just the normal MNKD muddling along as it has for so long now. At least we approach CFBE thanks to Martine, but it doesn’t appear to be happening any quicker or sooner than anticipated.
|
|
|
|
Post by Chris-C on Nov 6, 2023 11:56:47 GMT -5
|
|
|
|
Post by ptass on Nov 6, 2023 12:16:05 GMT -5
My guess is there’s no bad or disappointing news coming in this call. On the other hand, there’s no surprisingly excellent news either. Just the normal MNKD muddling along as it has for so long now. At least we approach CFBE thanks to Martine, but it doesn’t appear to be happening any quicker or sooner than anticipated. I'm looking forward to an update on the start date of the phase 2/3 clofazimine study. I believe it was to commence in August 2023 but the fire postponed that. Hopefully it will start before the end of the year. |
|
|
|
Post by standup on Nov 6, 2023 12:57:38 GMT -5
Could it be the growing belief that the increasingly popular GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro will significantly cut the demand for insulin injections in people with diabetes and, thus, have an affect on Afrezza as well?
Could this be why Afrezza sales appear to have hit a plateau?
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 6, 2023 13:12:16 GMT -5
No, I wouldn't think so. Although Afrezza can be used for T1 and T2, the majority of use so far is with Type 1. GLP-1 will not affect that.
It may have an effect on Type 2 use, but so far, Mike targets Type 1.
Once it starts catching on in Type 2, though, it probably will have some effect, but the market is so huge that there will still be plenty of room for Afrezza.
|
|
|
|
Post by radgray68 on Nov 6, 2023 13:56:04 GMT -5
Just a few thoughts I had on the unusual stagnation this quarter:
1. CFBE is not anticipated until Q4, which won’t report until February.
2. Endocrine department won’t see much growth until we have something to say “legally” about Afrezza’s superiority. Nothing anticipated until next summer on
that front.
3. The geopolitical climate is in a state not seen since the 1930’s before WWII. Speculative stocks, of which we belong, will naturally suffer during times of this tension.
4. Price moves in low volume aren’t as worrisome to me as high volume moves because it is easier to manipulate during low volume trading.
5. We want it WAY, WAY, WAY too much.
|
|
|
|
Post by sayhey24 on Nov 6, 2023 13:57:03 GMT -5
Could it be the growing belief that the increasingly popular GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro will significantly cut the demand for insulin injections in people with diabetes and, thus, have an affect on Afrezza as well? Could this be why Afrezza sales appear to have hit a plateau? No. People become diabetic because their body is not making enough of the hormone, insulin. GLP1s do not replace the hormone. They basically reduce the amount of food people eat so they do not need as much insulin but like every other T2 med they mask the problem so giving the PWD what they should have gotten day 1 gets delayed for another year or 2. The benefit of the GLP1 is weight reduction which happens when you don't eat. There is nothing wrong with losing a few pounds or in the case of GLP1 users lots of pounds. You can usually spot a GLP1 user a mile away with the drawn face. Afrezza sales have plateaued because the sale reps do not have the proper studies in their bags to sell it and most insurance companies do not cover it and few know you can buy direct for $99. Most afrezza uptake has been in the T1 community. This was never intended to be the target market and many thought it would not even get FDA approval for T1s. Two of the 3 studies now being done are for the T1s and the kids trial should be the big one. For the T2s they need to get great numbers from the India study and then they can try and get Medicare coverage which is the key to cracking the T2 market. |
|
|
|
Post by RainbowUnicorn on Nov 6, 2023 13:58:30 GMT -5
Damn the torpedoes... added 8000 shares at $3.75. David Dreman be my Sensei  |
|
|
|
Post by peppy on Nov 6, 2023 14:10:18 GMT -5
Could it be the growing belief that the increasingly popular GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro will significantly cut the demand for insulin injections in people with diabetes and, thus, have an affect on Afrezza as well? Could this be why Afrezza sales appear to have hit a plateau? Type 1's have to use insulin. The plateau? it has occurred to me people can not get into their endocrinologist because they are so busy with the demand for Semaglutide Injection. GLP-1 for type two's. 1800 dollars a month. It is said people have to stay on it, or they gain the weight back. Mathematics, More than 37 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes.
If all type two's were treated it would be the whole GDP. or something like that.  |
|
|
|
Post by JEvans on Nov 6, 2023 15:58:20 GMT -5
Symphony Scripts Breakdown Chart (2023 to date goes thru 10/27) | Scripts per week | 2020 | 2021 | 2022 | 2023 to date | Estimated 2023 | | Scripts in the 600s | 9 | 27 | 12 | 0 | 0 | | 700s | 32 | 24 | 26 | 4 | 4 | | 800s | 11 | 1 | 12 | 27 | 33 | | 900s | 0 | 0 | 2 | 12 | 15 | | Total Rx | 39,176 | 37,052 | 39,106 | 37,026 | 44,776 | | Total Rx $ | $70,760,000 | $72,875,000 | $82,140,000 | $81,920,000 | $99,066,047 | | Avg $ per Rx | $1,806 | $1,967 | $2,100 | $2,112 | $2,112 | | Avg Rx per week | 753 | 712 | 752 | 861 | 861 |
| | | | |
|
|
|
|
|
Post by sportsrancho on Nov 6, 2023 15:59:18 GMT -5
|
|
|
|
Post by sayhey24 on Nov 6, 2023 17:17:03 GMT -5
I always find this interesting "During these fasting periods, insulin levels decrease, allowing cells to become more receptive to insulin when eating resumes,” Huffman said. “This increased sensitivity helps regulate blood sugar levels more effectively" Why is that - decrease the pancreas released insulin and the cells become more sensitive? I also find it interesting that if you stop the spike with afrezza before the BG gets high you need a lot less afrezza. You would think if your cells are resistant to insulin then the BG level should not matter. Unless of course some thing else is going on blocking the receptors after the BG goes high and the pancreas has already released its insulin. |
|
|
|
Post by ptass on Nov 6, 2023 19:24:07 GMT -5
My guess is there’s no bad or disappointing news coming in this call. On the other hand, there’s no surprisingly excellent news either. Just the normal MNKD muddling along as it has for so long now. At least we approach CFBE thanks to Martine, but it doesn’t appear to be happening any quicker or sooner than anticipated. I'm looking forward to an update on the start date of the phase 2/3 clofazimine study. I believe it was to commence in August 2023 but the fire postponed that. Hopefully it will start before the end of the year. Also curious to hear details on the dpi manufacturing capacity increases expected to come online in 2024 that UTHR mentioned on the call. |
|
|
|
Post by cedafuntennis on Nov 6, 2023 19:55:52 GMT -5
Also with the end of the year, it is practically impossible to get an appointment with the endocrinologist. I tried to have a simple dental cleaning and nothing till late January...
|
|
